New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions with food allergies

The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies

Sarclisa Phase 3 trial met primary endpoint of progression free survival with newly diagnosed multiple myeloma not eligible for transplant

Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd alone

BioPhy launches AI platform to accelerate the drug development market

The company has raised US$4.5 million in funding for its AI operating system

Sun Pharma gets USFDA filing acceptance of new drug application for Deuruxolitinib

The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials

India has taken a lead in Preventive and Integrated Healthcare, says Dr Jitendra Singh

Dr. Singh proposes upskilling medicos with AI, Quantum and other newer technologies to meet the changing requirements of patient care

Nobel prize 2023 for medicine awarded to Katalin Karikó, Drew Weissman for research on mRNA vaccines to fight Covid-19

The discoveries by the two Nobel Laureates were critical for developing effective mRNA vaccines against COVID-19

Global health challenges can be resolved using digital technology: Dr Alain Labrique

LVPEI raises awareness on antimicrobial resistance among medical students

Antimicrobial Resistance (AMR) poses a significant threat to global healthcare systems and patient safety

Merck partners with California-based research group to study catalysis innovation through machine learning

Aim is to predict novel catalysts using machine learning (ML) and artificial intelligence (AI) techniques

Janssen Tremfya excels as psoriasis treatment, outshining IL-17s, says GlobalData

The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab